Clinical manifestations and related influencing factors of adverse drug reactions to Semaglutide

Mou Yuqin; Luo Yi; Wang Siqi; Tang Shiguo

doi:10.11986/j.issn.1673-873X.2024.06.18

Abstract：Objective To analyze the clinical manifestations and related influencing factors of adverse drug reactions(ADRs)to semaglutide,providing references for clinical treatment.Methods Clinical data from 597 patients treated with semaglu-tide at the Endocrinology Department of Chongqing Ninth People's Hospital from January 2022 to December 2023 were col-lected.Patients were assigned to two groups based on the occurrence of ADRs:the reaction group(n=177)and the non-re-action group(n=420).Data on patient's name,age,gender,body mass index(BMI),purpose of medication,semaglutide maintenance dose,and follow-up details or telephone calls were collected.Any discomfort post-medication was recorded thoroughly through outpatient or telephone follow-ups.Results The most common organ/system affected by semaglutide ADRs was the digestive system,accounting for 82.48％of cases.Among the 177 patients with ADRs,18 patients(10.16％)discontinued the drug due to intolerable ADRs,7 patients(3.95％)required hospitalization due to persistent ADR-related symptoms,and 2 patients(1.12％)died due to exacerbation of underlying diseases triggered by severe diarrhe-a.Significant differences between the two groups were observed in BMI levels,off-label drug use,and purpose of medication(P＜0.05).Multivariate logistic regression analysis revealed that low BMI,type 2 diabetes,and off-label drug use were factors influencing the occurrence of ADRs to semaglutide(P＜0.05).Conclusion Gastrointestinal ADRs are common with semaglutide,and it may also increase the risk of gallstone formation.It is recommended that semaglutide be used strictly ac-cording to indications,with an evaluation of the patient's digestive system and thyroid status before administration,and close monitoring of early and long-term ADRs during treatment.